ASX:OCC

Orthocell Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume669,530 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive OCC News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthocell and its competitors with MarketBeat's FREE daily newsletter.

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.

Innovating for the invisible ailment: the ASX-listers combatting chronic pain
July 13, 2021 | proactiveinvestors.com.au

Orthocell thrilled with positive nerve regeneration results
June 21, 2021 | proactiveinvestors.com.au

Orthocell unveils positive CelGro® nerve regeneration results in quadriplegic patients
June 21, 2021 | proactiveinvestors.com

Why the Orthocell (ASX:OCC) share price is flying higher today
June 21, 2021 | msn.com

Orthocell locks in patents in China and New Zealand for CelGro® soft tissue sutureless repair
June 16, 2021 | proactiveinvestors.com.au

Here’s why the Orthocell (ASX:OCC) share price is on the move today
June 15, 2021 | msn.com

New breakthrough in stem cells research paves the way for ASX regenerative medicine stocks
June 9, 2021 | msn.com

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation
June 7, 2021 | finance.yahoo.com

Orthocell welcomes further Asian patent protection for CelGro collagen rope
May 27, 2021 | proactiveinvestors.com.au

Orthocell higher on securing further Asian patent protection for CelGro® collagen rope
May 26, 2021 | proactiveinvestors.com.au

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:OCC
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.orthocell.com.au
Phone61 8 9360 2888
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$797,629.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow3.41
Book ValueA$0.11 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.32 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Orthocell.

1.6 Community Rank

Outperform Votes
Orthocell has received 6 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Orthocell has received 13 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Orthocell has received 68.42% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Orthocell and other stocks. Vote “Outperform” if you believe OCC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Orthocell does not currently pay a dividend.
Dividend Growth
Orthocell does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orthocell insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Orthocell (ASX:OCC) Frequently Asked Questions

What stocks does MarketBeat like better than Orthocell?

Wall Street analysts have given Orthocell a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orthocell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Orthocell's key executives?

Orthocell's management team includes the following people:

Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 51, Pay $150k)
Mr. Paul Anderson, CEO, MD & Exec. Director (Age 55, Pay $495.55k)
Ms. Leslie Wise J.D., Exec. Director
Ms. Nicole Jane Telford, Chief Financial Officer
Mr. Alex McHenry, Chief Operating Officer
Prof. Ming Hao Zheng, Chief Scientific Officer and Member of Medical & Scientific Advisory Board
Mr. Simon Lee Robertson B.Bus, CA, M Appl. Fin., Company Sec. (Age 61)

Who are some of Orthocell's key competitors?

Some companies that are related to Orthocell include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS) and Amplia Therapeutics (ATX).
View all of OCC's competitors.

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), Viralytics (VRACY), Genetic Technologies (GTG) and GP Strategies (GPX).

What is Orthocell's stock symbol?

Orthocell trades on the ASX under the ticker symbol "OCC."

How much money does Orthocell make?

Orthocell has a market capitalization of $0.00 and generates $797,629.00 in revenue each year.

What is Orthocell's official website?

The official website for Orthocell is www.orthocell.com.au.

How can I contact Orthocell?

The company can be reached via phone at 61 8 9360 2888.

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.